Antago-miR155-AuNP targets macrophages with high specificity in vivo.
Notes: (A–C) RAW264.7 cells were transfected with miR155 mimics by lipofectamine 2000. Expression of miR155 (A), IL-1β (B), and IL-10 (C) was analyzed by qPCR (mean ± SEM of three experiments). (D) Synthesis of miRNA-conjugated AuNP nanoparticles. Thiolated miRNA antagonist was added to solutions of citrate-stabilized gold colloid and attached through thiol-gold chemistry. (E) Size distribution of the conjugated AuNP analyzed by NTA. (F) Immunofluorescence confocal images of miRNA-AuNP in the livers, spleens, and hearts from the indicated groups, in which miRNA-AuNP was labeled with Cy3 (red) and nuclei were counterstained with Hoechst (blue). Scale bar =50 μm and applies to all images. (G) Schematic representation of the experimental procedure. OVX diabetic mice 4 weeks after operation were injected with control or antago-miR155 AuNP once a week for 2 weeks. Ten weeks after operation, cardiac function, morphology, and cellular changes were systematically analyzed. (H–J) qPCR data of miR155 (H), IL-1β (I), and IL-10 (J) expression in the hearts of OVX diabetic mice with NC or miR155 antagonist delivery (mean ± SEM of 3 mice in each group). *P<0.05, **P<0.01, and ***P<0.001.
Abbreviations: AuNP, gold nanoparticles; Hoechst, Hoechst 33258; IL-1β, interleukin-1β; IL-10, interleukin-10; NC, negative control; NTA, nanoparticle tracking analysis; OVX, ovariectomized; qPCR, quantitative polymerase chain reaction; SEM, standard error of the mean; STZ, streptozotocin.